The PennZone

  • Home
  • Non-profit
  • Books
  • Health
  • Marketing
  • Business
  • Music
  • Entertainment
  • Automotive

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • Ashley Russo Receives Linny Lifetime Achievement Award
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • BESTBUYSTORE opens its dropshipping model to independent merchants
  • America's Hometown Thanksgiving Parade in Plymouth, MA, on Saturday, November 21, 2026
  • Navigating a Changing Market: How AIX Group Is Responding to a Challenging Year
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST)
  • Wave Helicopters Takes FLIBS 2026 to New Heights

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • Canada's First Data Lakehouse Goes Global in Banking: Nabil Bank Becomes Nepal's First Bank to Implement a True Agentic Lakehouse Platform, DataNature
  • Latin GRAMMY-Winning Cuban-American Conductor Dr Yalil Guerra to Lead Pepperdine's Oklahoma!
  • Highsfield Showcases Earth Zoom Generator for Cinematic AI Videos
  • Patton AI Launches Patton Hive 4.5: Wartime Breakthroughs for Drones and Robots When GPS Goes Dark
  • Wisdom trumps wrinkles: 66% of Aussie women wouldn't turn back the clock

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Roots, Rhythm & Joy Invites Neighbors to Find Community Through Music
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • Stand Strong Fencing of Hatfield Turns Every October Project Into a Cancer Donation
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • Former Goddard Enterprises Managing Director Anthony Ali Joins STS Capital Partners as Managing Director and Partner
  • Heritage at Manalapan Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Homes
  • Good Organics Now at Pop Up Grocer NYC With October 30 Sampling Event
  • KeysCaribbean Announces Temporarily Reduced Rates At Village at Hawks Cay Villas
  • Commercial Manufacturing Validation Completed as November 10 FDA Milestone Approaches; Critical FDA Milestone Close: NRx Pharmaceuticals NAS DAQ: NRXP
  • Electives Launches "Electives for Everyone," Making Live Expert-Led Learning Available to Every Employee
  • Tax Tops the List as Wealthy Brits Plan Their Exit, La Vida Survey Finds
  • "The Tree of Cinema" Installation Brought Film History and Its Audiences Together at TIFF 2026
  • Detroit Lawyer Steals $600,000 Settlement Meant to Protect Child
  • The Great Junk Hunt Makes Its Highly Anticipated Stop in Philadelphia (Oaks)!
  • Heritage at South Brunswick Announces Special Townhome Mortgage Rate Buydown
  • Heritage at Hopewell Announces Limited-Time Mortgage Rate Buydown on Select Quick Move-In Townhomes
  • Air Force Veteran Sean Douglas Delivers Powerful Suicide Prevention Presentations to Hundreds of Marines at Camp Pendleton
  • Ashley Russo Receives Linny Lifetime Achievement Award
  • How to Choose a Heating Repair Company in Philadelphia
  • Renew Integrative Health Publishes Updated Peptide Therapy Guide to Help Patients Understand Their Options

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers - 157
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh - 117
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia - 107
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville - 103
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago - 103
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single - 101
  • World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026

Similar on PennZone

  • CoreVar Announces Cooking with AI, an Eight-Topic Live Webinar Series
  • Mr Hospital Bed Cites Hill Rom Hospital Bed Models Best Value Home Care Hospital Beds 2026
  • Navigating a Changing Market: How AIX Group Is Responding to a Challenging Year
  • 450 Million Revenue Run Rate, Global Telecom Reach and a New Digital Growth Opportunity Take Center Stage: IQSTEL, Inc. (N A S D A Q: IQST)
  • Sherri Horsey Darden: A Visionary Woman Building a Legacy of Inspiration, Community, and Excellence
  • Hospital Direct Medical Equipment Company Seeing Growth in Used Refurbished Medical Equipment Sales
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Nashville
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms
  • National Literacy and Workforce Readiness Crisis Sparks New Program Launching in Birmingham
  • New England Consulting Partners Celebrates 25 Years of Turnaround Management Solutions
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us